• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

New GSK chief taps WalMart exec, refocuses R&D efforts

July 26, 2017 By Sarah Faulkner

GlaxoSmithKlineGlaxoSmithKline‘s (NYSE:GSK) has reportedly named former WalMart executive Karenann Terrell as chief digital and technology officer, in a move to integrate digital technology across its pharmaceutical business.

This is among the many choices made by newly appointed chief executive Emma Walmsley to boost GSK’s ability to compete with rival pharma companies. GSK also recently nabbed former AstraZeneca executive, Luke Miels.

Terrell departed from WalMart as chief information officer in February and is slated to join GSK, along with Miels, in September.

“The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach,” Walmsley said in a statement. “As a member of the executive team, Karenann will have the scope to think radically about how we can exploit the latest opportunities and ultimately improve our business performance.”

Walmsley has signaled that she wants to improve the company’s returns by slashing programs that aren’t generating enough profit. As the drugmaker unveiled their second quarter financial results, she outlined a plan to streamline R&D and refocus the company’s research and commercial efforts.

The chief executive announced today that she would ditch more than 30 drug projects and that the company will direct 80% of its R&D budget to efforts in respitory and HIV/infectious disease. She also pointed to oncology and immuno-inflammation as potential areas of interest, according to Reuters.

Thirteen clinical programs got the axe, as well as 20 pre-clinical programs – they will either be stopped, partnered or divested. The company is also evaluating options for its rare disease unit, the newswire reported.

GSK plans to stop selling its diabetes drug, Tanzeum, and will also end a collaboration with Johnson & Johnson over an experimental rheumatoid arthritis drug.

“We’ve been too broadly spread,” Walmsley reportedly told journalists, adding that the company will also divest nearly 130 old drugs.

Britain’s largest drugmaker reported today that it brought in £7.32 billion in sales this quarter ($9.53 billion), growing 12% compared to the same period last year. That beat the Street’s revenue estimates of £7.26 billion ($9.48 billion).

GSK shares were trading at $40.95 in afternoon activity today, down -2.4%.

Material from Reuters was used in this report.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS